There were 947 press releases posted in the last 24 hours and 220,884 in the last 365 days.

PCRopsis™ RVD Enhancer makes PCRopsis™ Reagent RVD compatible with most specimen transport mediums

Reagent RVD + RVD Enhancer mediates direct PCR with specimens in diverse transport mediums.

Reagent RVD + RVD Enhancer offers a competitive price and workflow advantage to any laboratory performing PCR-based testing.”
— Pratik Sharma
MIAMI, FLORIDA, USA, March 25, 2021 /EINPresswire.com/ -- PCRopsisReagent RVD + PCRopsis™ RVD Enhancer offers a direct PCR solution for specimens in most non-inactivating transport mediums.

PCRopsis™ Reagent RVD alone has been repeatedly shown to facilitate extraction-free amplification of viral, bacterial, and mammalian specimens in universal viral transport (UVT) mediums, like BD™ Universal Viral Transport system. This is one of the most common specimen transport mediums in the U.S., although many other transport mediums are used in the U.S. and abroad.

Entopsis developed PCRopsis™ RVD Enhancer to expand the compatibility of PCRopsis™ Reagent RVD to process specimens in diverse transport mediums. PCRopsis™ Reagent RVD, when used in combination with PCRopsis™ RVD Enhancer, can process specimens in just about any non-inactivating transport medium. Compatible transport mediums now include viral transport mediums recommended by the Centers for Disease Control and World Health Organization, and even a simple phosphate buffered saline (PBS) solution.

“Reagent RVD + RVD Enhancer offers a competitive price and workflow advantage to any laboratory performing PCR-based testing”, said Pratik Sharma, VP of business development at Entopsis.

About Entopsis / PCRopsis
Entopsis was founded in 2011 to pursue the simple idea that an unbiased approach to diagnostics using bio-molecular profiles can be clinically and scientifically useful. The company is predominantly focused in the areas of oncology and infectious diseases, and exploring new areas lacking accurate diagnostics. PCRopsis™ technologies are based on Entopsis’ core platform, OpsisDxTM, and aim to streamline research and clinical applications, while decreasing costs. For more information, please visit www.Entopsis.com and www.PCRopsis.com

Pratik Sharma
Entopsis LLC
+1 8884075070
info@entopsis.com
Visit us on social media:
Twitter
LinkedIn